LABORATORY CORPORATION OF AMERICA HOLDINGS

Healthcare issues related to clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3152/S. 1546, the Patent Eligibility Restoration Act, provisions relating to patent subject matter eligibility; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; A draft of the Health Care Price Transparency Act 2.0 and a draft of the PRICE TAGS Act, provisions relating to lab price transparency; A draft of the Correct Coding Improvement Act, provisions relating to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development; and Federal policy related to Medicare coverage of colorectal cancer screening.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.